1. 2,3-dihydro-n-2-propynyl-1h-inden-1-amine-(1r)-hydrochloride
2. Agn 1135
3. Agn-1135
4. Azilect
5. N-2-propynyl-1-indanamine
6. N-propargyl-1-aminoindan Mesylate
7. Rasagiline
8. Rasagiline Hydrochloride
9. Tvp 101
10. Tvp 1022
11. Tvp-101
12. Tvp-1022
13. Tvp1022
1. 161735-79-1
2. Azilect
3. Rasagiline Mesilate
4. Tvp-1012
5. Agilect
6. (r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine Methanesulfonate
7. Rasagiline Methanesulfonate
8. Rasagiline Mesylate [usan]
9. Rasagiline (mesylate)
10. Rasagline Ratiopharm
11. Rasagiline (as Mesilate)
12. Lh8c2ji290
13. (r)-n-2-propynyl-1-indanamine Methanesulfonate
14. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, Methanesulfonate
15. Methanesulfonic Acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine
16. Ncgc00168774-01
17. Azilect (tn)
18. Mfcd08460604
19. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, Methanesulfonate
20. Rasagiline Mesilate (jan)
21. Rasagiline Mesylate (usan)
22. Dsstox_cid_27826
23. Dsstox_rid_82589
24. Dsstox_gsid_47848
25. Rasagiline Mesilate [jan]
26. Tvp1012
27. Cas-161735-79-1
28. Tvp 1012
29. Unii-lh8c2ji290
30. C12h13n.ch3so3h
31. Schembl158439
32. (1r)-2,3-dihydro-n-2-propynyl-1h-inden-1-amine Methanesulfonate
33. (r)-2,3-dihydro-n-2-propynyl-1-indenamine Mesylate
34. Chembl1201142
35. Dtxsid8047848
36. Hms3884d07
37. Rasagiline Mesylate [vandf]
38. (1r)-2,3-dihydro-n-2-propyn-1-yl-1h-inden-1-amine Mesylate
39. Act06733
40. Rasagiline Mesilate [mart.]
41. Tox21_112635
42. Ac-724
43. Rasagiline Mesylate [who-dd]
44. S2102
45. Akos005145768
46. Rasagiline Mesylate, >=98% (hplc)
47. Tox21_112635_1
48. Bs-1009
49. Ccg-267122
50. Tv 1012
51. 1h-inden-1-amine, 2,3-dihydro-n-2-propyn-1-yl-, (1r)-, Methanesulfonate (1:1)
52. Rasagiline Methanesulfonate [mi]
53. Ncgc00168774-02
54. Rasagiline Mesylate [orange Book]
55. (+)-agn-1135
56. Hy-14605
57. R0213
58. D02562
59. 735r791
60. Q-101873
61. Q27282989
62. (r)-n-2-propynyl-1-indanamine Methanesulphonate
63. Z1820079046
64. (1r)-2,3-dihydro-n-2-propynyl-1h-in Den-1-amine Methanesulfonate
65. (r)-n-(prop-2-ynyl)-2,3-dihydro-1h-inden-1-amine Methanesulfonate
66. (1r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine; Methanesulfonic Acid
67. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, Methanesulphonate
| Molecular Weight | 267.35 g/mol |
|---|---|
| Molecular Formula | C13H17NO3S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 267.09291458 g/mol |
| Monoisotopic Mass | 267.09291458 g/mol |
| Topological Polar Surface Area | 74.8 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 305 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Azilect |
| Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
| Active Ingredient | Rasagiline mesylate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 0.5mg base; eq 1mg base |
| Market Status | Prescription |
| Company | Teva |
| 2 of 4 | |
|---|---|
| Drug Name | Rasagiline mesylate |
| PubMed Health | Rasagiline (By mouth) |
| Drug Classes | Antiparkinsonian |
| Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
| Active Ingredient | Rasagiline mesylate |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | eq 0.5mg base; 0.5mg; 1mg; eq 1mg base |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharma; Apotex |
| 3 of 4 | |
|---|---|
| Drug Name | Azilect |
| Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
| Active Ingredient | Rasagiline mesylate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 0.5mg base; eq 1mg base |
| Market Status | Prescription |
| Company | Teva |
| 4 of 4 | |
|---|---|
| Drug Name | Rasagiline mesylate |
| PubMed Health | Rasagiline (By mouth) |
| Drug Classes | Antiparkinsonian |
| Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
| Active Ingredient | Rasagiline mesylate |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | eq 0.5mg base; 0.5mg; 1mg; eq 1mg base |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharma; Apotex |
Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Monoamine Oxidase Inhibitors
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
N04BD02
LOOKING FOR A SUPPLIER?
